KRAS and cancer: Remarkably, our study unexpectedly discovered that KRAS G12C–mutant cancer cells, whether they exhibit intrinsic or acquired resistance to KRAS G12C inhibitors, also display cross-resistance to other inhibitors targeting EGFR, IGF1R, MEK, or SHP2 (Figure 1).